针对钩端螺旋体病的DNA疫苗:文献综述
钩端螺旋体病由致病性钩端螺旋体引起,现有全菌体疫苗存在效力低、副作用多、免疫记忆差及缺乏跨血清型交叉保护等局限。本综述讨论近25年DNA疫苗研发中质粒载体、佐剂、接种途径及初免-加强方案等策略的最新进展,并探讨未来改进方向。
要点
- 现有钩端螺旋体病疫苗为全菌体疫苗,效力低且缺乏跨血清型交叉保护。
- DNA疫苗是传统疫苗研发的有前景替代方案。
- 近25年质粒载体、佐剂、接种途径及初免-加强方案等策略被用于提高DNA疫苗效力。
核心结论
- DNA疫苗是钩端螺旋体病传统疫苗研发的有前景替代方案,综述讨论了该领域最新且最有前景的进展及未来方向。
研究设计与样本
- 文献综述,检索范围未在摘要中报告。
主要发现
- 现有钩端螺旋体病疫苗为全菌体疫苗,存在效力低、副作用多、免疫记忆差及缺乏跨血清型交叉保护等局限。
- 近25年已开发多种提高DNA疫苗效力的新策略,包括新型质粒载体、佐剂、替代接种途径及初免-加强方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Leptospirosis is an infectious disease caused by pathogenic Leptospira species. The vaccines that are currently available for leptospirosis are composed of whole-cell preparations and suffer from limitations such as low efficacy, multiple side-effects, poor immunological memory and lack of cross-protection against different serovars of Leptospira spp. In light of the global prevalence of this disease, the development of a more effective vaccine against leptospirosis is of paramount importance. Genetic immunization is a promising alternative to conventional vaccine development. In the last 25years, several novel strategies have been developed for increasing the efficacy of DNA vaccines. Examples of such strategies include the introduction of novel plasmid vectors, adjuvants, alternate delivery routes, and prime-boost regimens. Herein we discuss the latest and most promising advances that have been made in developing DNA vaccines against leptospirosis. We also deliberate over the future directions that must be undertaken in order to improve results in this field.
引用
- Silveira MM, Oliveira TL, Schuch RA, et al. DNA vaccines against leptospirosis: A literature review. Vaccine. 2017. PMID: 28882437. doi:10.1016/j.vaccine.2017.08.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。